Novel Etanercept variants with improved therapeutical effect

Novel mutant variants of the fusion protein Etanercept with improved TNF neutralizing specificity and therapeutical effect, ameliorating the side effects associated to the clinical use of Etanercept.

Market need: Etanercept (Enbrel®) is one of the leading biologics for chronic inflammatory diseases such as rheumatoid arthritis, ankylosing spondylitis or psoriasis. It works by blocking TNF via a soluble TNFR2–Fc fusion. presenting several limitations:
Incomplete control of inflammatory cascades (e.g. chemokines), leaving a substantial part of the inflammatory axis intact.
Dose limitations and safety constraints.
Non specific activity against lymphotoxin (LTα), worsening susceptibility to infections
Incomplete responses or loss of efficacy in high proportion of patients.

Proposed solution: Inspired by viral immunomodulators, a new etanercept-derived bifunctional inhibitor by fusing TNFR2–Fc with a viral chemokine binding domain (SECRET) was engineered. This novel variant maintains full binding affinity and inhibitory activity against TNF while adding high affinity chemokine neutralization.
In vivo studies using a an arthritis mouse model showed that the fusion protein performed equivalently to double dose etanercept, demonstrating increased potency per mg. Additionally, this variant displays a >60 fold reduction in anti LTα activity, essentially abolishing LTα inhibition, preserving immune competence. The invention represents a next-generation etanercept, specifically optimized to modulate broader inflammatory networks.

Competitive advantages

Novel mechanism inspired by viral immunomodulators, •offering a mechanism unattainable by monoclonal antibodies or current TNF inhibitors.
Superior biological efficacy through dual inhibition of TNF and chemokines.
Demonstrated in vivo potency equivalent to higher doses of Etanercept.
Improved safety profile with preserved immune competence.